JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
Phase 2
200
about 2.9 years
18+
36 sites in AL, CA, CO +20
What this study is about
This trial is testing a treatment called bevacizumab in adults with Acute Respiratory Distress Syndrome (ARDS). Participants will either receive bevacizumab or a placebo. It lasts 1068 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Cohort C: bevacizumab
- 2.Take Cohort C: placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
bevacizumab
infusion
Secondary: Days of hospitalization up to and including Day 28, Improvements in oxygenation measured as change from baseline in PaO2/FiO2 ratio up to and including Day 28 (or discharge, whichever is earlier), Incidence and severity of adverse events (AEs) /adverse event of special interest (AESI) / serious adverse event (SAEs)